Alternative therapy of Alzheimer's disease via supplementation with choline acetyltransferase

Neuroscience Letters
Ai Ling FuMan Ji Sun

Abstract

Much evidence indicates that the memory and cognitive deficits of patients with Alzheimer's disease are closely associated with dysfunction of central cholinergic system. The degree of reduction of choline acetyltransferase activity in cerebral cholinergic neurons is significantly correlated with the severity of dementia or cognitive impairments observed in Alzheimer's disease. Therefore, Alzheimer's disease may be slowed by supplementation of exogenous choline acetyltransferase. Here we show that choline acetyltransferase mediated by TAT protein transduction domain passes through the blood-brain barrier and enters the neurons in mice, increasing choline acetyltransferase and neurotransmitter acetylcholine contents. The recombination TAT-choline acetyltransferase fusion protein injected intravenously improves the memory and cognitive dysfunction in Alzheimer's disease model mice induced by amyloid-beta peptide. Our results imply a novel and potentially effective way for Alzheimer's disease therapy.

References

Mar 1, 1972·Analytical Biochemistry·L P Chao, F Wolfgram
Feb 9, 2000·Trends in Pharmacological Sciences·S R Schwarze, S F Dowdy

❮ Previous
Next ❯

Citations

Apr 11, 2007·Bioscience, Biotechnology, and Biochemistry·Mi Jeong KimDong-Hoon Shin
Jun 7, 2014·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Mason Chin Pang LeungBelinda Garner
Jun 10, 2006·Biochemical and Biophysical Research Communications·Shao Ping WuMan Ji Sun
Feb 3, 2010·Pharmaceuticals·Xanthi Antoniou, Tiziana Borsello
Jun 24, 2017·American Journal of Alzheimer's Disease and Other Dementias·Ioana-Miruna Balmus, Alin Ciobica
Oct 4, 2017·Pharmacology Research & Perspectives·Qian LiManji Sun
Apr 30, 2015·Prague Medical Report·Somava Biswas, Sarbani Giri
Jan 11, 2007·Bioscience, Biotechnology, and Biochemistry·Mi Jeong KimDong-Hoon Shin
Dec 20, 2013·Angewandte Chemie·Jing XuEmmanuel A Theodorakis
Jun 24, 2017·The Journal of Pharmacy and Pharmacology·Sheila Adela Villa-CedilloOdila Saucedo-Cárdenas
Jul 7, 2005·International Journal of Geriatric Psychiatry
Dec 6, 2005·Brain Research Bulletin·Gunnar P H Dietz, Mathias Bähr
Jul 20, 2018·ACS Omega·Qian LiManji Sun
Jul 9, 2008·Experimental Gerontology·Xu Ling LiMan Ji Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.